(Total Views: 613)
Posted On: 05/05/2020 11:29:18 AM
Post# of 149265
Nice paper ... at least in terms of what I can understand.
I realize this is the wrong vehicle, but I was hoping the paper would include a recitation of leronlimab's entire MOA relating to COVID.
Although anecdotal, I was also hoping the paper would include the 100% survival metric for all patents after Montefiore.
Also missing the virus in blood finding.
Hope there is a mechanism to communicate these details to FDA.
I realize this is the wrong vehicle, but I was hoping the paper would include a recitation of leronlimab's entire MOA relating to COVID.
Although anecdotal, I was also hoping the paper would include the 100% survival metric for all patents after Montefiore.
Also missing the virus in blood finding.
Hope there is a mechanism to communicate these details to FDA.
(1)
(0)Scroll down for more posts ▼
